Genotype-Guided Antiplatelet Therapy: JACC Review Topic of the Week.

ABSTRACT: The clinical efficacy and safety of antiplatelet agents vary among patients. Consequently, some patients are at increased risk of recurrent ischemic events during treatment. This interindividual variability can be a result of genetic variants in enzymes that play a role in drug metabolism. The field of pharmacogenomics explores the influence of these genetic variants on an individual's drug response. Tailoring antiplatelet treatment based on genetic variants can potentially result in optimized dosing or a change in drug selection. Most evidence supports guiding therapy based on the CYP2C19 allelic variants in patients with an indication for dual antiplatelet therapy. In ticagrelor-treated or prasugrel-treated patients, a genotype-guided de-escalation strategy can reduce bleeding risk, wher

SUBMITTER: van den Broek WWA 

PROVIDER: S-EPMC11495226 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature